Related Experiment Videos
Chronotherapy of growth factors
1Division of Medical Oncology, Samuel S. Stratton Department of Veternas Affairs, Albany, NY 12208, USA.
Abstract:
Circadian coordination of the components of the hematopoietic system, immune system, and host-tumor balance in animals and humans have been demonstrated. Preclinical studies provide evidence that when within-the-day exogenous protein growth modulators such as EPO, G-CSF, IL-1, IL-2, TNF, or IFN are administered to animals, they determine to a large extent the magnitude of the hematopoietic, immunologic, toxic, and antitumor response. Optimal circadian timing of therapeutic proteins with minimal toxicity (e.g. EPO, CSF) should be further explored to investigate whether lower doses could be used or intervals prolonged with equal or greater drug efficacy. For antitumor efficacy, optimal circadian timing of growth factors may lower host toxicity, which may allow higher doses to be more safely utilized to more reliably induce significant anticancer activity.
Insights
Optimal timing for therapeutic proteins like EPO and G-CSF can enhance anti-cancer effects and reduce toxicity. Further research into circadian drug administration is crucial for improving cancer treatment efficacy and patient outcomes.
Area of Science:
- Chronobiology
- Immunology
- Oncology
- Pharmacology
Background:
- Circadian rhythms influence hematopoietic, immune, and host-tumor systems in humans and animals.
- Exogenous protein growth modulators (e.g., EPO, G-CSF, IL-1, IL-2, TNF, IFN) administered during the day impact hematopoietic, immunologic, toxic, and antitumor responses.
Purpose of the Study:
- To explore the optimal circadian timing of therapeutic proteins for minimizing toxicity and maximizing efficacy.
- To investigate if altered dosing schedules (lower doses or prolonged intervals) can maintain or improve drug effectiveness.
- To determine if precise timing of growth factors can enhance anticancer activity by reducing host toxicity.
Main Methods:
- Review of preclinical studies on the effects of exogenous protein growth modulators.
- Analysis of the relationship between administration time and hematopoietic, immunologic, and antitumor responses.
- Exploration of potential benefits of circadian-timed administration for therapeutic proteins like EPO and CSF.
Main Results:
- Preclinical evidence suggests that the timing of growth modulator administration significantly influences response magnitude.
- Optimal circadian timing of therapeutic proteins may allow for reduced dosage or extended intervals without compromising efficacy.
- Circadian-timed growth factors show potential for lowering host toxicity, enabling safer dose escalation for improved anticancer activity.
Conclusions:
- Optimal circadian timing of therapeutic proteins is a promising strategy for enhancing cancer treatment.
- Further research into chronotherapy with agents like EPO and CSF could lead to improved efficacy and reduced side effects.
- Understanding and applying circadian principles in drug delivery can optimize antitumor responses and patient safety.